Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis

Fig. 4

Serum levels of MMP-3 and CXCL13 in AAV patients before and 6 months after the initiation of treatment. a Comparison of MMP-3 and CXCL13 levels between highly active AAV before treatment and remission 6 months after treatment. The titers of markers were measured in paired serum samples (before and 6 months after the initiation of treatment) from 52 patients with AAV [36 microscopic polyangiitis (MPA) and 16 granulomatosis with polyangiitis (GPA)]. Each line connects data obtained on one patient. b Comparison of MMP-3 and CXCL13 levels between patients in remission (n = 52) and those not in remission (n = 17) 6 months after the initiation of treatment. The 17 patients not in remission (10 MPA and 7 GPA) had mildly active AAV (median BVAS 5, range 3–6). Each dot represents one patient. Box plots show the median and IQR. Whiskers indicate the most extreme points within 1.5-fold of the IQR of the box. ***p < 0.001. n.s. Not significant. AAV, antineutrophil cytoplasmic antibody-associated vasculitis

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us